(Q50733321)

18 March 2018

title

Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis. (English)

1 reference

18 March 2018

main subject

immunization

0 references

Neisseria meningitidis

1 reference

Duzhang Zhu

1

1 reference

18 March 2018

Vicki Barniak

2

1 reference

18 March 2018

Ying Zhang

3

1 reference

18 March 2018

Bruce Green

4

1 reference

18 March 2018

Gary Zlotnick

5

1 reference

18 March 2018

language of work or name

English

0 references

publication date

31 March 2006

1 reference

18 March 2018

published in

Vaccine

1 reference

18 March 2018

volume

24

1 reference

18 March 2018

issue

26

1 reference

18 March 2018

page(s)

5420-5425

1 reference

18 March 2018

Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B meningitis.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Immunologic response of man to group B meningococcal polysaccharide vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Passive immunization with Neisseria meningitidis PorA specific immune sera reduces nasopharyngeal colonization of group B meningococcus in an infant rat nasal challenge model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Immunization with Haemophilus influenzae Hap adhesin protects against nasopharyngeal colonization in experimental mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

New strategies for using mucosal vaccination to achieve more effective immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Human immunity to the meningococcus. II. Development of natural immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Human immunity to the meningococcus. I. The role of humoral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

Growth Requirements of the Meningococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

inferred from DOI database lookup

7 January 2021

based on heuristic

Serum and Nasal Secretion Immune Response in Meningococcal Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

inferred from DOI database lookup

7 January 2021

based on heuristic

Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.051

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.03.051

1 reference

18 March 2018

PubMed ID

16621173

1 reference

18 March 2018